Cargando…

Furosemide and spironolactone doses and hyponatremia in patients with heart failure

BACKGROUND: Hyponatremia, a marker of disease severity and prognosis, has been associated with various clinical factors and drug use, especially diuretics. METHODS: This observational prospective cohort study enrolled patients hospitalized at the University Hospital Center Split because of heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velat, Ivan, Bušić, Željko, Jurić Paić, Marina, Čulić, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397681/ https://www.ncbi.nlm.nih.gov/pubmed/32746925 http://dx.doi.org/10.1186/s40360-020-00431-4

Ejemplares similares

Circulating thyroid hormones and clinical parameters of heart failure in men
por: Turić, Iva, et al.
Publicado: (2023)

Clinical effects of combined treatment by optimal dose of furosemide and spironolactone on diastolic heart failure in elderly patients
por: CHEN, ZHI-HAO, et al.
Publicado: (2016)

Furosemide/spironolactone: Hypotension: case report
Publicado: (2022)

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
por: Ng, Tien M.H., et al.
Publicado: (2020)

Addition of Tolvaptan Compared With Increased Dose of Furosemide in Heart Failure Patients With Chronic Kidney Disease Under Furosemide Treatment
por: Tanaka, Toshiki, et al.
Publicado: (2018)

Intravenous furosemide in decompensated heart failure: do not protocolize dosing but the desired effect!
por: de Grooth, Harm-Jan S, et al.
Publicado: (2014)

Use, tolerability and compliance of spironolactone in the treatment of heart failure
por: Lachaine, Jean, et al.
Publicado: (2011)

Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
por: Adin, Darcy, et al.
Publicado: (2021)

‘Door-to-furosemide’ timing: early treatment of heart failure
por: Piazza, Vito
Publicado: (2019)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Evaluation of diuretic efficiency of intravenous furosemide in patients with advanced heart failure in a heart failure clinic
por: Herrera-Leaño, Nancy, et al.
Publicado: (2023)

Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose–Response Curves in Worsening Refractory Congestive Heart Failure
por: Paterna, Salvatore, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Proteomic differences among patients with heart failure taking furosemide or torsemide
por: Cooper, Lauren B., et al.
Publicado: (2022)

Hyponatremia and Renal Venous Congestion in Heart Failure Patients
por: Caraba, Alexandru, et al.
Publicado: (2021)

Hyponatremia in Heart Failure: Pathogenesis and Management
por: Rodriguez, Mario, et al.
Publicado: (2019)

The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia
por: Alotaibi, Abdulmalik S, et al.
Publicado: (2020)

Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
por: Yu, Yuan, et al.
Publicado: (2022)

Dose of furosemide before admission predicts diuretic efficiency and long‐term prognosis in acute heart failure
por: Blázquez‐Bermejo, Zorba, et al.
Publicado: (2021)

Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective
por: Ahmed, Fozia Z., et al.
Publicado: (2021)

Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2015)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Association of early administration of furosemide with improved oxygenation in patients with acute heart failure
por: Mikami, Takafumi, et al.
Publicado: (2021)

Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry)
por: Dunlap, Mark E., et al.
Publicado: (2017)

Racial differences and mortality risk in patients with heart failure and hyponatremia
por: Miles, Jeremy A., et al.
Publicado: (2019)

Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution
por: Sica, Domenic A., et al.
Publicado: (2018)

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
por: Manolis, Antonis A, et al.
Publicado: (2019)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

Hyponatremia and heart failure: the overlooked piece of the puzzle
Publicado: (2016)

Hyponatremia and heart failure: the overlooked piece of the puzzle
por: Koza, Yavuzer, et al.
Publicado: (2016)

Management of Hyponatremia in Heart Failure: Practical Considerations
por: Şorodoc, Victoriţa, et al.
Publicado: (2023)

The combined impact of hyponatremia and hematocrit on the risk for 90-day readmission and death in patients with heart failure: dilutional hyponatremia versus depletional hyponatremia
por: Rao, Jiahuan, et al.
Publicado: (2023)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Continuous versus intermittent use of furosemide in patients with heart failure and moderate chronic renal dysfunction
por: Zheng, Zhigui, et al.
Publicado: (2021)

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
por: Nodari, Savina, et al.
Publicado: (2010)

Comparison of Different Furosemide Regimens in the Treatment of Acute Heart Failure: A Meta-Analysis
por: Huang, Youpan, et al.
Publicado: (2022)

Efficacy and safety of spironolactone for the treatment of patients with acute heart failure: A protocol for systematic review
por: Feng, Yan-lin, et al.
Publicado: (2020)

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)
por: Coffman, Melissa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l5osk1h6qtnfml1nreo6k0jtd4